Compare NetEase Inc (NTES) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Viatris Inc — how do they compare? NetEase Inc trades at $126.85 (market cap $86.14B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: NetEase Inc is far larger — about 4.4× Viatris Inc's market cap, and Viatris Inc pays the higher dividend (2.83%). Which is the better fit depends on your goals.
| NTES | VTRS | |
|---|---|---|
Market Cap | $86.14B | $19.79B |
Sector | Media | Health |
52-Week High | $159.34 | $17.39 |
52-Week Low | $109.26 | $8.74 |
Enterprise Value | $62.61B | $32.00B |
Dividend Yield | 2.25% | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $129.57, down 1.31% over the past day, with a bullish technical outlook supported by moving averages. The company reported strong Q1 2026 earnings of $2.53 EPS, beating expectations, and maintains robust profitability with a 29.84% net income margin. Recent news highlights international expansion and a Zacks Strong Buy upgrade, while the stock offers a dividend with the next payment scheduled for June 18, 2026.
The outlook for NTES is positive, driven by earnings growth, cash flow strength, and analyst optimism, with a 34.66% upside to price targets. Key risks include China market volatility and competitive pressures in gaming. The stock presents a value opportunity with a P/E of 17.26, but investors should monitor geopolitical and regulatory developments.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
